Back to search results

Geriatric Assessment for Head and Neck Cancer Treatment

This study is for older adults (age 60 and above) with head and neck cancer who are undergoing chemotherapy and radiation. It compares two approaches: one where you receive a special "geriatric assessment" (GA) to help manage your care and side effects, and another where you receive usual care. The GA approach also includes support for your family caregiver. Researchers want to see if the GA approach can reduce treatment-related side effects, like nausea or fatigue, up to three months after treatment ends. They are also looking at how well patients and caregivers like the GA approach and if it helps reduce emergency room visits. The study plans to enroll 36 participants.

Study design
This study is an interventional trial that compares two groups: one receiving a geriatric assessment-driven intervention and another receiving usual care. It plans to enroll 36 participants.
What's involved
If you join, you will have regular clinical visits and may undergo geriatric assessments at baseline, 4 weeks, and one month after treatment. You will be followed for up to 3 months after completing treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed up at 1 and 3 months after completing study interventions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07225855

Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer and Their Family Caregivers

Recruiting
NAAges 18+InterventionalSupportive care
City of Hope Medical Center
~36 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Best PracticeElectronic Health Record ReviewHealth CommunicationInterviewOffice VisitPractical Geriatric Assessment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of grade 2-5 non-hematologic treatment-related toxicities
Measured over Up to 3 months after completion of treatment

Conditions

Localized Head and Neck Carcinoma

Explore related trials

Malignant Head and Neck Neoplasm

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Arya Amini · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Arya Amini
[email protected]
626-218-2247
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PATIENT: Documented written informed consent of the participant
PATIENT: Diagnosis of non-metastatic head and neck cancer
PATIENT: Age: ≥ 60 years
PATIENT: Patient must be scheduled to undergo curative-intent, definitive radiation with or without concurrent chemotherapy or postoperative radiation with or without concurrent chemotherapy
PATIENT: Patients must have at least one geriatric assessment as assessed by the modified Geriatric 8 (G8) tool
PATIENT: Family caregivers (FCGs) are highly encouraged to participate but this is not required. Patients without FCGs will be eligible to participate in the study. FCGs will be randomized to the same arm as their corresponding patients
PATIENT: Ability to read and understand English
CAREGIVER: A family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care
CAREGIVER: Ability to read and understand English
CAREGIVER: Age 18 years or older

What this trial measures

  • Proportion of grade 2-5 non-hematologic treatment-related toxicitiesUp to 3 months after completion of treatment

    Will be assessed in patients using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Will be summarized using descriptive statistics. For continuous variables, descriptive statistics such as number, mean, standard deviation, standard error, median (range) etc. will be provided. For categorical variables, counts and percentages will be provided. Observed toxicities will be summarized by type, severity, and attribution. Rates will be estimated along with the 95% exact binomial confidence interval.